{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:08:01Z","timestamp":1761844081902},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,3,17]],"date-time":"2011-03-17T00:00:00Z","timestamp":1300320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The purpose of this study was to determine whether LAPTM4B over\u2010expression is associated with the prognosis and chemotherapy resistance in patients with stages III and IV epithelial ovarian carcinoma, i.e., patients with peritoneal metastasis or lymph node metastasis of epithelial ovarian carcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>LAPTM4B expression was evaluated in 10 normal ovarian and 113 stages III\u2013IV ovarian carcinomas specimens by Western blotting analyses and immunohistochemistry. Univariate and multivariate analyses were performed to determine the association between LAPTM4B expression and prognosis and the relationship between LAPTM4B over\u2010expression and chemotherapy resistance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Western blotting analysis demonstrated that LAPTM4B was overexpressed in ovarian cancers, and immunohistochemistry results revealed that 80 patients were LAPTM4B over\u2010expression. The five\u2010year overall survival (OS) rates for patients with high LAPTM4B expression and low LAPTM4B expression were 27.36% and 90.7%, respectively (hazard ratio\u2009=\u200920.611, 95% CI: 5.916\u201371.808, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). The five\u2010year progression\u2010free survival (PFS) rate was 17.68% for patients in the high\u2010expression group and 84.42% for patients in the low\u2010expression group (hazard ratio\u2009=\u200917.852, 95% CI: 6.31\u20135.935, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001); The presence of chemotherapy resistance was significantly associated with LAPTM4B expression (OR: 36.609, 95% CI: 4.737\u2013282.941, <jats:italic>P<\/jats:italic>\u2009=\u20090.0006).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>LAPTM4B over\u2010expression is an independent factor in stages III\u2013IV epithelial ovarian carcinoma prognosis and chemotherapy resistance, and it may be an important potential biomarker. J. Surg. Oncol. 2011;104:29\u201336. \u00a9 2011 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jso.21912","type":"journal-article","created":{"date-parts":[[2011,3,17]],"date-time":"2011-03-17T13:10:28Z","timestamp":1300367428000},"page":"29-36","source":"Crossref","is-referenced-by-count":43,"title":["Over\u2010expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer"],"prefix":"10.1002","volume":"104","author":[{"given":"Mingzhu","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanling","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rouli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,3,17]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.55.1.10"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2010.02.044"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2007.00824.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v10.i11.1555"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206832"},{"key":"e_1_2_5_7_2","first-page":"881","article-title":"Biological function of a novel gene over expressed in human hepatocellular carcinoma","volume":"113","author":"Liu JJ","year":"2000","journal-title":"Chin Med J"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2004.10.004"},{"key":"e_1_2_5_9_2","first-page":"1077","article-title":"LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma","volume":"20","author":"Yang Y","year":"2008","journal-title":"Oncol Rep"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/IGC.0b013e3181e02f90"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25689"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.10.025"},{"key":"e_1_2_5_13_2","article-title":"Ovarian cancer including Fallopian tube cancer and Primary peritoneal cancer","author":"Robert J","year":"2009","journal-title":"NCCN clinical practice guidelines in oncology. v.2."},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v11.i18.2704"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-009-0659-4"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21489"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.01.025"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-182"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2090"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjso.21912","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.21912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T12:07:49Z","timestamp":1697630869000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.21912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,17]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1002\/jso.21912"],"URL":"https:\/\/doi.org\/10.1002\/jso.21912","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,17]]}}}